Press Releases
-
Aug 2, 2017
- Company Announces Record Total BioMarin Revenues of $317.4 million in the Second Quarter of 2017Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2017 2016 % Change 2017 2016 % Change Total BioMarin Revenues
-
Aug 2, 2017- Recent 4e13 vg/kg Data Indicates Majority of Patients in Open-Label Phase 1/2 Study Expected to Achieve Factor VIII Activity Levels in the Normal Range
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it will expand its development plan for BMN 270, its investigational gene therapy for hemophilia A, to include an additional Phase...
-
Jul 31, 2017- Company to Also Provide Data and Development Plan Update on 4e13 vg/kg Dose of Investigational Gene Therapy Product BMN 270 for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 18, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
-
Jul 18, 2017-- Agreement terms resolve global patent proceedings regarding Sarepta’s sale of EXONDYS 51® (etep-lirsen) and future Duchenne muscular dystrophy (DMD) exon-skipping products --
CAMBRIDGE, Mass. and SAN RAFAEL, Calif., July 18, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of...
-
Jul 11, 2017
BioMarin Provides BMN 270 Data at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress Initiation of Phase 3 Registrational Study Planned for Q4 2017 with 6e13 vg/kg Dose 97%...
-
Jun 30, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the company submitted a Biologics License Application (BLA) on Friday, June 30, 2017 to the U.S. Food and Drug Administration (FDA) for...
-
Jun 16, 2017Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in a late breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH)...
-
Jun 1, 2017Dosing includes all ages from birth for this fatal and rapid pediatric neurodegenerative condition
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission (EC) has granted marketing authorization for Brineura™ (cerliponase alfa), the first treatment approved in the...
-
May 31, 2017- Goldman Sachs 38th Annual Global Healthcare Conference on June 13 in Rancho Palos Verdes, CA
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global...
-
May 4, 2017- First Quarter 2017 Total BioMarin Revenues Increase 28% Year over Year to $304 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2017 2016 % Change Total BioMarin Revenues $ 304 $ 237 28 % Aldurazyme Net Product...
-
May 2, 2017- Deutsche Bank's 42nd Annual Health Care Conference on May 3 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in Deutsche Bank's 42nd Annual Health Care...
-
Apr 27, 2017Brineura™ is the first FDA-approved treatment for this fatal neurodegenerative condition
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to slow the loss of ambulation in symptomatic...
-
Apr 21, 2017One of the First Therapies to Receive Positive CHMP Opinion Using New Accelerated Assessment Process
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has...
-
Apr 20, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May...
-
Apr 13, 2017Retains exclusive U.S. rights until October 1, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that it has entered into a settlement agreement with Par Pharmaceutical that resolves patent litigation in the United States (U.S.)...
-
Feb 23, 2017- Full Year 2016 Total BioMarin Revenues Increase 26% Year over Year to $1.12 billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2016 2015 % Change 2016 2015 % Change Total...
-
Feb 15, 2017Oral Presentations to Include Research and Data in Ongoing Studies for the Treatment of Morquio A Syndrome and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the 13th Annual WORLDSymposium™ being held February...
-
Feb 8, 2017- Leerink Partners 6th Annual Global Healthcare Conference on February 16 in New York City
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Leerink Partners 6th Annual Global...
-
Feb 7, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Feb 1, 2017First Product to be Eligible for Access to PRIME in Hemophilia
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's...
-
Jan 8, 2017Factor VIII Levels Maintained for All High Dose Patients at 34-50 Weeks
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for...
-
Jan 3, 2017
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 35th Annual J.P. Morgan Healthcare Conference on
-
Dec 12, 2016
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
-
Nov 3, 2016Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona
SAN RAFAEL, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Oct 27, 2016Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 % Change 2016 2015 % Change Total...
-
Oct 19, 2016Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose
SAN RAFAEL, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic...
-
Oct 13, 2016Phase 1/2 Study Expected to Resume by End of 2016
SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United...
-
Oct 11, 2016
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Sep 21, 2016BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008)
SAN RAFAEL, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it intends to seek a review of the Patent Trial and Appeal Board (PTAB) of...
-
Sep 14, 2016CHMP Opinion and EU Decision Expected Q3 2017
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
-
Sep 8, 2016Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase in Adults with PKU
SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company's products and...
-
Sep 6, 2016Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017
SAN RAFAEL, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced a program update for cerliponase alfa, a recombinant human tripeptidyl peptidase 1...
-
Aug 31, 2016Citi's 11th Annual Biotech Conference September 7 in Boston
SAN RAFAEL, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that management will participate in the Gene Therapy Panel at Citi's 11th Annual...
-
Aug 24, 2016For the third consecutive year, BioMarin ranks in top 10 on list
SAN RAFAEL, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most...
-
Aug 9, 2016
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common...
-
Aug 8, 2016
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its...
-
Aug 4, 2016Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2016 2015 % Change 2016 2015 % Change Total BioMarin Revenue
-
Jul 27, 2016Potential First Treatment for Fatal, Rare, Brain Disease in Children
SAN RAFAEL, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the submission...
-
Jul 27, 20166 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10%
SAN RAFAEL, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today positive interim results of an open-label Phase 1/2 study of BMN 270, an...
-
Jul 21, 2016Conference call and web-cast to be held Wednesday, July 27th at 4:05pm ET
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII...
-
Jul 18, 2016
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment...
-
Jul 14, 2016
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Jun 20, 2016Investor event to be held in Orlando following the July 27 oral presentation at the WFH meeting
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for...
-
May 31, 2016
SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization...
-
May 4, 2016Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas
SAN RAFAEL, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate...
-
May 3, 2016EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016
SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA) has granted BioMarin's request for...
-
Apr 28, 2016First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2016 2015 % Change Total BioMarin Revenue $ 236.7 $ 202.9 16.7 % Vimizim Net...
-
Apr 21, 2016European Commission Grants BMN 250 Orphan Drug Designation to Treat Ultra-Rare Condition
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an...
-
Apr 20, 2016Two High Dose Patients Show Increasing Levels of Factor VIII Above 50%
SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an...
-
Apr 20, 2016New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocity for up to 12 months with Increases of 46%-65% from Baseline
SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic...
-
Apr 18, 2016Key development updates will include preliminary data with BMN 270, gene therapy for hemophilia A, and one year data with vosoritide for achondroplasia
SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City....
-
Apr 12, 2016
SAN RAFAEL, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin,...
-
Mar 24, 2016
SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A,...
-
Mar 21, 2016In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed
SAN RAFAEL, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- BioMarin announced today that the pivotal Phase 3 PRISM-2 study (formerly referred to as 165-302) of pegvaliase met the primary endpoint of...
-
Mar 3, 2016Cowen and Company 36th Annual Health Care Conference on March 8 in Boston
SAN RAFAEL, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Mar 2, 201680% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001)
SAN RAFAEL, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced positive 48-week results from its Phase 1/2 pivotal study for cerliponase alfa, a...
-
Mar 1, 2016
SAN RAFAEL, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of patients with...
-
Feb 29, 2016Oral Presentations Include Results From Phase 1/2 Study on Cerliponase Alfa in Children With CLN2 Disease, a Form of Batten Disease
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the 12th
-
Feb 29, 2016On Rare Disease Day, BioMarin Highlights Its Commitment to Patients With Morquio A, MPS VI and Phenylketonuria (PKU) and Their Caregivers With Personalized Resources
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering...
-
Feb 25, 2016Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2015 2014 % Change 2015 2014 % Change Total BioMarin Revenue...
-
Jan 28, 2016
SAN RAFAEL, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Jan 14, 2016Marketing Application in Europe Remains Under Review
SAN RAFAEL, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter...
-
Jan 11, 2016Reveglucosidase Alfa Trends Positive in Respiratory Muscle Strength and Endurance Endpoints in Patients Previously Treated With Enzyme Replacement Therapy
SAN RAFAEL, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a fusion...
-
Jan 5, 2016
SAN RAFAEL, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Jan 4, 2016
SAN RAFAEL, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that David Pyott has been elected to the company's board of directors. Mr. Pyott is...
-
Dec 18, 2015
SAN RAFAEL, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that they...
-
Nov 24, 2015
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that NASDAQ has halted trading of the company's stock. The Peripheral and Central...
-
Nov 24, 2015
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Company's presentation from the Peripheral and Central Nervous System...
-
Nov 24, 2015If Approved, Kyndrisa Would Become the First Disease-Modifying Therapy for Patients With Duchenne Muscular Dystrophy in the United States Amenable to Exon 51 Skipping
SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S....
-
Nov 23, 2015Recommendation Provides Patient Access to Treatment for Ultra-Rare Condition With Reimbursement
SAN RAFAEL, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the The National Institute for Health and Care Excellence (NICE), NHS England...
-
Nov 20, 2015
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) posted briefing materials prepared...
-
Nov 20, 2015
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in...
-
Nov 16, 2015
SAN RAFAEL, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Ernst & Young Global Limited awarded BioMarin CEO Jean-Jacques Bienaimé the...
-
Oct 29, 2015Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 % Change 2015 2014 % Change Total BioMarin Revenue...
-
Oct 27, 2015Credit Suisse Healthcare Conference on November 11 in Scottsdale, Arizona
SAN RAFAEL, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will...
-
Oct 15, 2015Advisory Committee Meeting Scheduled for November 24, 2015
SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S....
-
Oct 15, 2015
SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
-
Oct 12, 2015
SAN RAFAEL, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dr. Melita Irving, Clinical Geneticist, Guy's and St Thomas' NHS Foundation...
-
Oct 1, 2015Strengthens and Expands BioMarin's Leadership Position Serving PKU Patients with Rights to Both Kuvan® (sapropterin dihydrochloride) and Pegvaliase Beyond North America
SAN RAFAEL, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that it has acquired all global rights to Kuvan® (sapropterin dihydrochloride) and...
-
Sep 30, 2015
SAN RAFAEL, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present research results at the 20th International Congress...
-
Sep 29, 2015Priority of U.S. Patent Claims Confirmed by U.S. Patent Trial and Appeal Board (PTAB)
SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of...
-
Sep 28, 2015BMN 270 is the First AAV-Factor VIII Gene Therapy to be Investigated in a Clinical Trial Setting for Patients With Hemophilia A
SAN RAFAEL, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 270, an...
-
Sep 18, 2015
SAN RAFAEL, Calif., Sept. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories,...
-
Sep 2, 2015Morgan Stanley Global Healthcare Conference on September 16 in New York
SAN RAFAEL, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will...
-
Sep 1, 2015Adds Novel Program to Established Offering of Personalized Patient Support Services
SAN RAFAEL, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the introduction of kNOWyourDuchenne, a program to help families and physicians...
-
Aug 31, 2015Oral Presentations Include Long-Term Safety and Efficacy with Pegvaliase for Control of Blood Phenylalanine in Adults with PKU and a Review of the Ongoing Development Program for Reveglucosidase Alfa for Late Onset Pompe Disease
SAN RAFAEL, Calif., Aug. 31, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in two oral and 19 poster presentations at the...
-
Aug 24, 2015Talazoparib is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer
SAN FRANCISCO and SAN RAFAEL, Calif., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Medivation, Inc. (Nasdaq:MDVN) and BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that they have entered into an...
-
Aug 19, 2015For the Second Consecutive Year, BioMarin Ranks in Top 10 on List
SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has been ranked 10th on Forbes magazine's 2015 list of the "World's Most...
-
Aug 19, 2015
SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease...
-
Aug 3, 2015In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y
Financial Highlights ($ in millions, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2015 2014 % Change 2015 2014 % Change Total BioMarin Revenue $ 250.5 $...
-
Jul 27, 2015
SAN RAFAEL, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the...
-
Jul 20, 2015ABRAZO Phase 2 Study Meets Protocol-Specified Criteria to Expand Enrollment
SAN RAFAEL, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP)...
-
Jul 15, 2015
SAN RAFAEL, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
-
Jun 29, 2015FDA Grants Priority Review Status
SAN RAFAEL, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the submission...
-
Jun 25, 2015
SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Medicines Agency (EMA) has validated the Marketing Authorization...
-
Jun 17, 201550% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group
SAN RAFAEL, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111...
-
Jun 15, 2015
SAN RAFAEL, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that EY awarded BioMarin CEO Jean-Jacques Bienaimé the EY Entrepreneur Of The...
-
Jun 8, 2015
SAN RAFAEL, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European...
-
Jun 4, 2015
SAN RAFAEL, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...
